硝苯地平药物市场：依剂型、适应症、通路及地区划分

硝苯地平药物市场规模预计在 2025 年为 12.567 亿美元，预计到 2032 年将达到 23.57 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 9.4%。

硝苯地平是一种钙通道阻断剂，用于治疗高血压和心绞痛引起的胸痛。钙通道阻断剂透过放鬆动脉壁肌肉，增加心臟的血液和氧气供应来发挥作用。硝苯地平于1983年首次核准用于医疗用途。硝苯地平透过阻断心臟和动脉肌肉细胞中的钙离子通道来发挥作用。这使得血管扩张，从而降低血压并减轻心臟负担。硝苯地平有短效和长效锭剂形式，已被证明能有效控制血压并缓解全球数百万人的胸痛。

市场动态

在预计预测期内，患有高血压和心血管疾病的人数不断增加以及老龄化人口不断增加是推动全球硝苯地平药物市场成长的关键因素。

此外，市场参与企业正热衷于推出新的硝苯地平产品，预计这将在预测期内促进全球硝苯地平市场的成长。例如，学名药开发商AVET Pharmaceuticals于2019年9月18日推出了硝苯地平软胶囊。该产品有10毫克和20毫克两种规格可供选择。本产品是钙拮抗剂Procardia的AB级学名药，进一步丰富了Avet强大的非专利口服固体製剂製剂产品组合。

然而，预计专利到期、监管挑战、副作用、替代疗法的可用性、治疗模式的转变以及定价压力将在预测期内阻碍全球硝苯地平药物市场的成长。

研究的主要特点

• 本报告对全球硝苯地平药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率(CAGR)。
• 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
• 全球硝苯地平剂量市场的主要企业会根据以下参数进行分析，例如公司亮点、产品系列、关键亮点、财务绩效和策略。
• 预计本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球硝苯地平药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球硝苯地平药物市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 合併、收购和合作

4. 全球硝苯地平药物市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 2020 年至 2032 年全球硝苯地平药物市场（以剂型划分）

• 介绍
• 锭剂
• 缓释片
• 胶囊
• 其他（舌下片、喷雾剂、贴片等）

6. 全球硝苯地平药物市场（依适应症划分），2020 年至 2032 年

• 介绍
• 高血压
• 心绞痛
• 雷诺现象
• 其他（早产、血管痉挛性疾病等）

7. 全球硝苯地平药物市场（依通路划分），2020-2032 年

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年按地区分類的全球硝苯地平药物市场

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第九章 竞争态势

• 公司简介
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • Sanofi SA
  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH（诺华公司的一个部门）
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Apotex Inc.

第 10 章 章节

• 参考
• 调查方法
• 关于出版商

Nifedipine Medication Market is estimated to be valued at USD 1,256.7 Mn in 2025 and is expected to reach USD 2,357.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.

Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.

Market Dynamics:

A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.

Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet's robust portfolio of generic oral solid products.

However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global nifedipine medication market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nifedipine medication market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited , Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division) Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd, and Apotex
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nifedipine medication market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nifedipine medication market

Global Nifedipine Medication Market Detailed Segmentation:

• By Dosage Form:
  • Tablets
  • Extended-release Tablets
  • Capsules
  • Others (Sublingual tablets/spray, Patches and Others)
• By Indication:
  • Hypertension
  • Angina Pectoris
  • Raynaud's Phenomenon
  • Others (Pre-term labor, vasospastic conditions and Others)
• By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (a Novartis division)
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Dosage Form
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Nifedipine Medication Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Nifedipine Medication Market, By Dosage Form, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Extended-Release Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Capsules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Sublingual tablets/spray, Patches and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Nifedipine Medication Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Angina Pectoris
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Raynaud's Phenomenon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Pre-term labor, vasospastic conditions and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Nifedipine Medication Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. 8. Global Nifedipine Medication Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Sub-region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Company Profile
  • Pfizer Inc
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • AstraZeneca PLC
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Teva Pharmaceutical Industries Ltd
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sanofi S.A.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Johnson & Johnson
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • GlaxoSmithKline plc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Lupin Limited
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sandoz International GmbH (a Novartis division)
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Dr. Reddy's Laboratories Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Torrent Pharmaceuticals Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Apotex Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Analyst Views

10. Section

• References
• Research Methodology
• About us